research Drug eruptions in dermatology
Skin reactions to drugs are common and can be deadly, usually requiring stopping the drug and may be better prevented with genetic testing in the future.
Search
for
Sort by
Research
510-540 / 1000+ results 
research Steroid sulfatase inhibitors
Steroid sulfatase inhibitors could potentially treat hormone-related disorders like certain cancers, hair loss, acne, and improve cognitive dysfunction.
research Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital
Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.
research Severe cutaneous adverse reactions to drugs
Some drugs can cause rare but potentially deadly skin reactions, and early treatment and avoiding the drug again are key.
research Sulfatase inhibitors: a patent review
The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research Application of Baricitinib in Dermatology
Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
research Efficacy of oral tofacitinib in moderate to severe alopecia areata, totalis and universalis at the tertiary care hospital, Karachi
Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
research Contact immunotherapy‐resistant alopecia areata totalis/universalis reactive to topical corticosteroid
Topical corticosteroids can help treat severe alopecia areata when other treatments fail.
research Baricitinib as an effective treatment for lichen planopilaris
Baricitinib may effectively treat lichen planopilaris.
research PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands
PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
research The Role of Tofacitinib in the Management of Alopecia Totalis
Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
research New agents for cancer chemoprevention
Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
research Topical Tacrolimus, Clobetasol, and Minoxidil (TCM) for Primary Cicatricial Alopecias: A Retrospective Analysis of Clinical Outcomes and Safety
TCM is an effective and safe treatment for primary cicatricial alopecias.
research Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
research Doxetaxel: new indication. Prostate cancer: a few more weeks.
Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
research Methotrexate in the treatment of steroid-dependent asthma
Methotrexate reduced the need for steroids in asthma patients without worsening their condition.
research Protection against cyclophosphamide‐induced alopecia and inhibition of mammary tumor growth by topical 1,25‐dihydroxyvitamin D3 in mice
Rubbing vitamin D3 on skin can help prevent hair loss from chemotherapy and slow breast tumor growth in mice.
research Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014)
Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
research Tofacitinib therapy for children with severe alopecia areata
Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
research Lilly arthritis drug approved for alopecia
The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Medications affecting the insulin-like growth factor 1/growth hormone axis, including teprotumumab, somatostatin analogs, and anti-calcitonin gene-related peptide monoclonal antibodies, are associated with elevated reporting odds of alopecia in women: A pharmacovigilance study
Some drugs linked to growth hormones may increase the chance of hair loss in women.
research Bicalutamide
research Tofacitinib in a Recalcitrant Case of Alopecia Areata
Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
research CASE REPORT: BIOLOGICAL THERAPY ASSOCIATION, CASE REPORT OF A PATIENT WITH ANKYLOSING SPONDYLITIS AND ALOPECIA AREATA
Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Identification of drug-specific public TCR driving severe cutaneous adverse reactions
Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.